PCVXVaxcyte Inc
Company Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Very Bullish
80
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest & Investment Income
Other Income / (Expense), net
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/ACompany Overview
Name
52W High
52W Low
Market Cap
Dividend Yield
Price/earnings
P/E
Dividends
No dividend
Sentiment
Score
Very Bullish
80
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Income Statement
Total Revenue
Operating Revenue
Total Gross Profit
Total Operating Income
Net Income
EV to EBITDA
EV to Revenue
Price to Book value
Price to Earnings
Additional Data
Selling, General & Admin Expense
Research & Development Expense
Total Operating Expenses
Interest & Investment Income
Other Income / (Expense), net
Total Other Income / (Expense), net
Earnings History
- Estimated
- Reported, beat
- Reported, missed
Estimated EPS
Reported EPS
N/AUpcoming Earnings
Company Info
CEO
Grant E. Pickering
Location
California, USA
Exchange
Nasdaq
Website
https://vaxcyte.com
Summary
Vaxcyte, Inc.
Company Info
CEO
Grant E. Pickering
Location
California, USA
Exchange
Nasdaq
Website
https://vaxcyte.com
Summary
Vaxcyte, Inc.
Community Research
Research from investors like you
Be the first to share your analysis on PCVX
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.
Symbol's posts
Vaxcyte: Is the Big Vaccine Test Coming?
Vaxcyte: Is the Big Vaccine Test Coming?
is getting close to a major Phase 3 readout for VAX 31. VAX 31 is a vaccine for pneumococcal disease. The trial is called EXPAND. A strong result could make the vaccine a real competitor to older shots. It could also open the door to a bigger market. The company still needs to prove the vaccine is safe and works well. I’m watching this one closely because a clean result could really change how people see the stock.
Watching Vaxcyte closely for the phase 3 data
Watching Vaxcyte closely for the phase 3 data
Anyone has any idea about how the upcoming Phase 3 data for Vaxcyte will turn out? If they can successfully prove their 31-valent vaccine is superior, it could be a total game changer for in the competitive pneumococcal market. What are your thoughts on their chances against the current industry leaders?
No more topics to show
